Topics

Videos

Albert Thigpen, co-founder, Talentwise Consulting, explains how to use these tactics in order to anticipate the future US healthcare policy environment.

Access Insights 2024: Reassessing Pricing and Commercialization Approaches

Albert Thigpen, co-founder, Talentwise Consulting, offers highlights of the drug commercialization panel that he participated in.

Access Insights 2024: Key Nuggets Surrounding the Chess Endgame

Articles

A panel dives into the current and future outlook of healthcare policies. 

Access Insights 2024: Playing the Chess Endgame 

Session dives into how healthcare policy implementation impacts stakeholders long-term.  

Access Insights 2024: Practicing Proactivity by Mapping Out Future Chessboard Moves

William Sarraille, professor, University of Maryland Francis King Carey School of Law, discusses other standout sessions at this year’s Access Insights conference.

Access Insights 2024: Notable Breakout Sessions

The session dives into the obstacles surrounding data usability, mandate compliance, initial adoption, and limitations in this arena. 

Access Insights 2024: Analyzing Drug Pricing and Reimbursement Data Amid a New Wave of CMS Price Requirements 

William Sarraille, professor, University of Maryland Francis King Carey School of Law, discusses breakout session and the impact of healthcare policies on manufacturing and commercialization. 

Access Insights 2024: Playing the Chess Endgame: Healthcare Policies Targeting Drug Commercialization

The conference’s opening keynote sets the scene for 2025 and the years to come. 

Access Insights 2024: Commercialization’s Financial Headwinds and Tailwinds

When it comes to navigating the complex clinical and commercial landscape for specialty drugs—including hurdles in access to these critical but costly therapies—today’s specialty pharmacies are bringing more skills and services to the table.

Specialty Pharmacy: The Trends Shaping Best Practices

As the dust settles on the first round of Medicare negotiations, not everything is what it seems.


Market Access